Certara

Certara is a drug-development services and software company that combines biosimulation, predictive analytics, regulatory expertise and technology-enabled services to help pharmaceutical, biotechnology and clinical research organisations make decisions from discovery through market access. Its work spans modeling and simulation, biometrics and data science, regulatory strategy, real-world evidence and artificial intelligence applied to drug development.

The company sells a portfolio of specialist software platforms. Phoenix is a biosimulation platform spanning drug discovery through commercial stages; Simcyp covers physiologically-based pharmacokinetic modeling; Pinnacle 21 handles data standardisation and validation for clinical trial submissions; and GlobalSubmit supports regulatory submissions. Other products include Certara IQ for development decision-making, BaseCase for value communication and market access, SEND Explorer for nonclinical datasets, D360 for discovery-research data informatics, Certara.AI and CoAuthor for AI-assisted scientific and regulatory writing.

Certara employs more than 1,550 people in over 30 countries, and more than 28% of them hold PhDs. Its client base exceeds 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries. The company's services cover modelling and simulation, biometrics and data science, regulatory strategy, drug-development support, and real-world evidence and market access.